Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

The HIV treatment landscape has further evolved with the introduction of LAI therapies, offering alternatives to daily oral ...

"This is the first phase III trial to demonstrate that a two-drug regimen without an integrase inhibitor is noninferior to ...

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

INSTIs belong to a category of drugs known as integrase inhibitors. INSTIs are well-established drugs. Doctors often use ritonavir (Norvir) as a booster drug for protease inhibitors. Due to their ...

Without the means to enter a cell, HIV cannot replicate. Integrase inhibitors work by blocking the incorporation of HIV's DNA ...

Two of these medications are from a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs) and are usually taken together in a single pill. A third medication – from either the ...

The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir. ViiV claimed the latter compound ...

investigational third-generation integrase inhibitor (INSTI), demonstrates strong antiviral activity and positive safety results across multiple dose levels in people with HIV-1, supporting ...

Juluca combines GSK’s already approved integrase inhibitor Tivicay (dolutegravir) with Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine), to produce a regimen that ...

today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and cardiometabolic complications over the next five ...